Abstract | AIM: METHODS: Wild-type (WT) and CD36KO mice were fed chow diet and fenofibrate for two weeks. TG concentrations and lipoprotein profiles were assessed during fasting and in the postprandial state in plasma; intestinal mucosa and lymph were collected after oral fat loading for both treatment groups. RESULTS:
Fenofibrate treatment markedly suppressed the postprandial TG response in CD36KO along with decreased apoB-48 levels in plasma. HPLC analysis depicted the decrease of TG content in chylomicrons (CM) and CM remnant-sized lipoproteins contributed to this suppression, suggesting that CM and CM remnant production in the intestines might be attenuated by fenofibrate. ApoB-48 and TG levels in intestinal lymph were markedly reduced after treatment. Intestinal mRNA expression of apoB was also reduced in the postprandial state after fenofibrate administration without affecting any other genes related to CM assembly and production. CONCLUSION:
Fenofibrate reduces PHTG in CD36KO partially through attenuating intestinal CM production.
|
Authors | José C Sandoval, Yumiko Nakagawa-Toyama, Daisaku Masuda, Yoshihiro Tochino, Hajime Nakaoka, Ryota Kawase, Miyako Yuasa-Kawase, Kazuhiro Nakatani, Miwako Inagaki, Kazumi Tsubakio-Yamamoto, Tohru Ohama, Makoto Nishida, Masato Ishigami, Issei Komuro, Shizuya Yamashita |
Journal | Journal of atherosclerosis and thrombosis
(J Atheroscler Thromb)
Vol. 17
Issue 6
Pg. 610-8
(Jun 30 2010)
ISSN: 1880-3873 [Electronic] Japan |
PMID | 20351468
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- CD36 Antigens
- Chylomicrons
- Fenofibrate
|
Topics |
- Animals
- CD36 Antigens
(deficiency)
- Chylomicrons
(biosynthesis)
- Fenofibrate
(pharmacology)
- Hypertriglyceridemia
(drug therapy, prevention & control)
- Intestinal Mucosa
(metabolism)
- Metabolic Syndrome
- Mice
- Mice, Knockout
- Postprandial Period
|